NCT05293873View on ClinicalTrials.gov

Outcomes of Autologous Bone Marrow-derived Mononuclear Cell Transplantation in the Management of Neurological Sequelae

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

March 30, 2023

Study Completion Date

June 30, 2023

Conditions
Sequelae of Injuries of Head
Interventions
BIOLOGICAL

autologous bone marrow-derived mononuclear cell transplantation

Bm-MNC will be transplanted at baseline, and the second transplantation will be performed 6 months after the first transplantation

OTHER

Rehabilitation therapy

Rehabilitation therapy

Trial Locations (1)

100000

Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi

All Listed Sponsors
lead

Vinmec Research Institute of Stem Cell and Gene Technology

OTHER

NCT05293873 - Outcomes of Autologous Bone Marrow-derived Mononuclear Cell Transplantation in the Management of Neurological Sequelae | Biotech Hunter | Biotech Hunter